"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 10 | 2 | 12 |
| 2011 | 3 | 4 | 7 |
| 2012 | 9 | 0 | 9 |
| 2013 | 8 | 3 | 11 |
| 2014 | 13 | 0 | 13 |
| 2015 | 12 | 4 | 16 |
| 2016 | 8 | 1 | 9 |
| 2017 | 17 | 0 | 17 |
| 2018 | 12 | 1 | 13 |
| 2019 | 12 | 1 | 13 |
| 2020 | 9 | 1 | 10 |
| 2021 | 12 | 0 | 12 |
| 2022 | 10 | 0 | 10 |
| 2023 | 17 | 1 | 18 |
| 2024 | 9 | 0 | 9 |
| 2025 | 13 | 0 | 13 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
a-synuclein preformed fibrils suppress cell cycle progression and glycolytic flux in glioblastoma cells. Exp Cell Res. 2026 Apr 15; 457(2):114970.
-
Synergistic Effects of Honokiol on Camptothecin-triggered Apoptosis of Drug-resistant Glioblastoma Cells via CDK1-mediated G2/M Arrest and Intrinsic ROS-Mitochondrion-dependent Pathway. Anticancer Res. 2026 Feb; 46(2):633-649.
-
Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures. Nat Cancer. 2025 Nov; 6(11):1761-1776.
-
Magnolol Traverses the Blood-brain Barrier and Enhances Temozolomide-induced Intrinsic Apoptosis of Glioblastoma Cells via a p53 Redox Signaling Mechanism. Anticancer Res. 2025 Nov; 45(11):5001-5017.
-
Acrolein-induced PKM2 modification drives NETosis and glioma progression. Free Radic Biol Med. 2025 Dec 16; 241:567-581.
-
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape. Nat Neurosci. 2025 Nov; 28(11):2231-2246.
-
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival. Hum Vaccin Immunother. 2025 Dec; 21(1):2556591.
-
Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions. Nature. 2025 08; 644(8078):1097-1106.
-
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. J Neurooncol. 2025 Oct; 175(1):453-461.
-
NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma. Cancer Res Commun. 2025 Jun 01; 5(6):960-972.